Tal Imbar

Dr. Tal Imbar

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Fertility and Sterility
Verified
Journal Article
Closed access
TITal Imbar
Tal Imbar
IEIris Eisenberg
Iris Eisenberg

16 January 2012 in Human Reproduction
Verified
Journal Article
Open access
PDF file
TITal Imbar
Tal Imbar
SKShahar Kol
Shahar Kol
FLFrancine Lossos
Francine Lossos
YBYuval Bdolah
Yuval Bdolah
AHA. Hurwitz
A. Hurwitz
RHRonit Haimov-Kochman
Ronit Haimov-Kochman
Triggering ovulation by GnRH agonist (GnRHa) in GnRH antagonist IVF protocols coupled with adequate luteal phase support has recently been suggested as a means to prevent ovarian hyperstimulation syndrome (OHSS). Our objective was to examine the outcome of fresh embryo transfer (f-ET) after triggering ovulation by GnRHa and providing intensive luteal phase supplementation, compared with that of the next first frozen–thawed embryo transfer (ft-ET) after cycles with the same protocol and cryopreservation of all the embryos. We performed a cohort study at a university-based IVF clinic. The study population was patients at high risk for OHSS. A daily dose of 50 mg i.m. progesterone in oil and 6 mg of oral 17-β-estradiol initiated on oocyte retrieval day in the f-ET group (n= 70). In the ft-ET group (n= 40) the embryos were cryopreserved and transferred in the next cycle. The live birth rate per f-ET was 27.1 versus 20% in the ft-ET groups [P = 0.4; rate ratio = 1.36 (0.65–2.81)]. The implantation, pregnancy and spontaneous abortion rates were comparable in both groups. None of the patients developed OHSS. In this observational cohort study, we showed that triggering ovulation with GnRHa and intensive luteal phase support is a promising new modality to prevent OHSS without the cost of cycle cancellation, ET deferral and reduced clinical pregnancy rates. Confirmation of these findings by RCTs is now required.

1 January 2017 in Fertility and Sterility
Verified
Journal Article
Closed access
IEIris Eisenberg
Iris Eisenberg
NNNeta Nahmias
Neta Nahmias
MPMichal Novoselsky Persky
Michal Novoselsky Persky
CGCaryn Greenfield
Caryn Greenfield
DGDebra Goldman-Wohl
Debra Goldman-Wohl
TITal Imbar
Tal Imbar

1 January 2015
Verified
Book Chapter
Closed access
PDF file
IEIris Eisenberg
Iris Eisenberg
NKNoora Kotaja
Noora Kotaja
DGDebra Goldman-Wohl
Debra Goldman-Wohl
TITal Imbar
Tal Imbar

18 June 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
GKGilad Karavani
Gilad Karavani
PWPeera Wasserzug-Pash
Peera Wasserzug-Pash
TMTalya Mordechai-Daniel
Talya Mordechai-Daniel
DBDvora Bauman
Dvora Bauman
MKMichael Klutstein
Michael Klutstein
TITal Imbar
Tal Imbar
In vitro maturation of oocytes from antral follicles seen during tissue harvesting is a fertility preservation technique with potential advantages over ovarian tissue cryopreservation (OTC), as mature frozen and later thawed oocyte used for fertilization poses decreased risk of malignant cells re-seeding, as compared to ovarian tissue implantation. We previously demonstrated that in vitro maturation (IVM) performed following OTC in fertility preservation patients, even in pre-menarche girls, yields a fair amount of oocytes available for IVM and freezing for future use. We conducted a retrospective cohort study, evaluating IVM outcomes in chemotherapy naïve patients referred for fertility preservation by OTC that had oocyte collected from the medium with attempted IVM. A total of 133 chemotherapy naïve patients aged 1–35 years were included in the study. The primary outcome was IVM rate in the different age groups – pre-menarche (1–5 and ≥6 years), post-menarche (menarche-17 years), young adults (18–24 years) and adults (25–29 and 30–35 years). We demonstrate a gradual increase in mean IVM rate in the age groups from 1 to 25 years [4.6% (1–5 years), 23.8% (6 years to menarche), and 28.4% (menarche to 17 years)], with a peak of 38.3% in the 18–24 years group, followed by a decrease in the 25–29 years group (19.3%), down to a very low IVM rate (8.9%) in the 30–35 years group. A significant difference in IVM rates was noted between the age extremes – the very young (1–5 years) and the oldest (30–35 years) groups, as compared with the 18–24-year group (p < 0.001). Importantly, number of oocytes matured, percent of patients with matured oocytes, and overall maturation rate differed significantly (p < 0.001). Our finding of extremely low success rates in those very young (under 6 years) and older (≥30 years) patients suggests that oocytes retrieved during OTC prior to chemotherapy have an optimal window of age that shows higher success rates, suggesting that oocytes may have an inherent tendency toward better maturation in those age groups.

1 June 2014 in Fertility and Sterility
Verified
Journal Article
Closed access
TITal Imbar
Tal Imbar
DGDaniela Galliano
Daniela Galliano
APAntonio Pellicer
Antonio Pellicer
NLNeri Laufer
Neri Laufer